RECURRENT MALIGNANT GLIOMA

This study is testing a drug called tipifarnib in children and young adults whose advanced cancers have a specific genetic change in a gene called HRAS. The goal is to see if the drug can shrink tumors and control the disease. Participants take the drug as a pill or through a fee…

This study is testing a drug called larotrectinib in children and young adults (ages 1-21) whose advanced solid tumors, lymphomas, or histiocytic disorders have returned or not responded to standard treatments. The drug is given to patients whose tumors have a specific genetic ch…

This small, early-stage study is testing whether the immunotherapy drug pembrolizumab can help control the growth of recurrent malignant brain tumors (gliomas) in a specific group of patients. The drug works by activating the body's own immune system to attack cancer cells. Resea…

This early-phase trial is testing a new type of personalized immunotherapy for patients with malignant brain tumors (gliomas) that have returned or stopped responding to standard treatments. Doctors collect a patient's own immune cells (T-cells), genetically modify them in a lab …

This is an early-stage safety study for a new type of CAR T-cell therapy designed for adults with a specific type of recurrent brain cancer called glioblastoma. The main goals are to find the safest dose and understand the side effects. Doctors will collect a patient's own immune…

This study is testing a targeted drug called selpercatinib in children and young adults with advanced or returning cancers that have specific changes in a gene called RET. The goal is to see if the drug can shrink tumors and control the cancer's growth. Participants take the drug…

This study is testing a drug called ensartinib in children and young adults whose advanced cancers have specific genetic changes (ALK or ROS1). The goal is to see if the drug can shrink tumors or stop them from growing in patients whose cancer has come back or hasn't responded to…

This study is testing a drug called ivosidenib in children and young adults (ages 1-21) whose cancers have returned or not responded to standard treatments. The drug is given as a daily pill and is designed to specifically block cancer growth in tumors that have a particular gene…

This early-stage study is testing the safety of a new two-part treatment for aggressive brain tumors that have returned after standard therapy. Doctors place genetically modified stem cells directly into the brain during surgery, hoping these cells will make the tumor more sensit…

This study is testing a drug called erdafitinib in children and young adults with advanced cancers that have returned or not responded to standard treatments. It is for patients whose tumors have specific genetic changes (FGFR mutations). The goal is to see if the drug, which is …

This study is testing a new, experimental type of MRI scan designed to see brain tumors (gliomas) in more detail. The goal is to see if this scan can provide better information about the tumor's biology and how it might respond to treatment. The study involves people with brain t…

This study aims to understand which treatment sequences work best for patients whose aggressive brain tumors have returned. Researchers will analyze the medical records of about 1,000 patients to see how different chemotherapy and targeted drug combinations affect survival and ti…